The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure

  • G. A. Turini
  • H. R. Brunner


Patients with congestive heart failure often reach a state when the compensatory increase in vascular tone impairs pump performance. They fail to excrete sodium and lack the ability to maintain normal sodium balance. During recent years, it has been shown that renin, via angiotensin II, plays an important role in blood pressure homeostasis and in various forms of hypertensive diseases. It has also become apparent that it participates in the vasoconstriction of congestive heart failure, and may contribute to its impaired sodium-handling.


Congestive Heart Failure Renin Secretion Oral Captopril Arterial Pressure Response Saralasin Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tobian L, Tomboullan A, Janecek J (1959) Effect of high perfusion pressures on the granulation of juxtaglomerular cells in an isolated kidney. J Clin Invest 38: 605PubMedCrossRefGoogle Scholar
  2. 2.
    Vander AJ, Miller R (1964) Control of renin secretion in the anesthetized dog. Am J Physiol 207: 537PubMedGoogle Scholar
  3. 3.
    Davis JO (1973) The control of renin release. Am J Med 55: 333–350CrossRefGoogle Scholar
  4. 4.
    Brunner HR, Laragh JH, Baer L, et al. (1972) Essential hypertension. Renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441–449PubMedCrossRefGoogle Scholar
  5. 5.
    Vander AJ (1965) Effect of catecholamines and the renal nerves on renin secretion in anesthetized dogs. Am J Physiol 209: 659PubMedGoogle Scholar
  6. 6.
    Brunner HR, Baer L, Sealey JE, Ledingham JGG, Laragh JH (1970) Influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest 49: 2128PubMedCrossRefGoogle Scholar
  7. 7.
    Page IH, Bumpus FM (eds) (1974) Angiotensin. Springer, Berlin Heidelberg New YorkGoogle Scholar
  8. 8.
    Laragh JH, Stoerk HC (1957) A study of the mechanism of secretion of the sodium-retaining hormone (aldosterone). J Clin Invest 36: 383–392PubMedCrossRefGoogle Scholar
  9. 9.
    Ganong WF, Biglieri EG, Mulrow PJ (1966) Mechanisms regulating adrenocortical secretion of aldosterone and glucocorticoids. Recent Prog Horm Res 22: 381PubMedGoogle Scholar
  10. 10.
    Pals DT, Masucci FD, Sipos F et al. (1971) A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 29: 664–672PubMedGoogle Scholar
  11. 11.
    Streeten DHP, Anderson GH, Freiburg JM et al. (1975) Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. N Engl J Med 292: 657–662PubMedCrossRefGoogle Scholar
  12. 12.
    Davis JO, Howell DS (1953) Mechanisms of fluid and electrolyte retention in experimental preparations in dogs. II. With thoracic inferior vena cava constriction. Circ Res 1: 171PubMedGoogle Scholar
  13. 13.
    Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H (1978) Congestive heart failure in normotensive man. Haemodynamics, renin and angiotensin II blockade. Br Heart J 40: 1134PubMedCrossRefGoogle Scholar
  14. 14.
    Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O (1971) Angiotensinconverting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure and synthesis. Biochemistry 10: 4033PubMedCrossRefGoogle Scholar
  15. 15.
    Watkins L Jr, Burton JA, Haber E, Cant JR, Smith FW, Berger C (1976) The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 57: 1606–1617PubMedCrossRefGoogle Scholar
  16. 16.
    Curtiss C, Cohn JN, Vrobel T, Franciosa JA (1978) Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58: 763PubMedGoogle Scholar
  17. 17.
    Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ (1978) Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58: 770PubMedGoogle Scholar
  18. 18.
    Ondetti MA, Rubin B, Cushman DW (1977) Design of specific inhibitors of angiotensinconverting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444PubMedCrossRefGoogle Scholar
  19. 19.
    Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry DN (1977) A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet I: 775–778CrossRefGoogle Scholar
  20. 20.
    Turini GA, Brunner HR, Grbic M, Waeber B, Gavras H (1979) Improvement of chronic congestive heart failure by oral captopril. Lancet 1: 1213–1215PubMedCrossRefGoogle Scholar
  21. 21.
    Levine TB, Carlyle PF, Gron KA, Franciosa JA, Cohn JN (1979) Hemodynamic and clinical response to captopril in congestive heart failure. Circulation 59,60: 11–39Google Scholar
  22. 22.
    Adler R, Chatterjee J, Ports T et al. (1979) Beneficial hemodynamic effects of an angiotensin converting enzyme inhibitor in chronic refractory heart failure. Am J Cardiol 43: 404Google Scholar
  23. 23.
    Davis R, Ribner HS, Keung E, Sonnenblick EH, Lejemtel TH (1979) Effect of captopril in heart failure. N Engl J Med 301: 117–121PubMedCrossRefGoogle Scholar
  24. 24.
    Mason DT, Hermanovich J, Evensen M, Awan NA (1980) Oral captopril in ambulatory management of severe congestive heart failure; sustained beneficial effects of ventricular function with 6 months therapy shown by cardiac catheterization, nuclear scintigraphy, echocardiography, treadmill exercise and symptomatology. Am J Cardiol 45: 411CrossRefGoogle Scholar
  25. 25.
    Mason DT, Awan NA, Hermanovich J et al. (1979) Oral captopril in congestive heart failure: efficacy by cardiac catheterisation, forearm plethysmography, nuclear scintigraphy, echography, treadmill exercise and symptoms. Circulation 59,60: 11–230Google Scholar
  26. 26.
    Adler R, Chatterjee K, Ports T et al. (1979) Sustained beneficial haemodynamic effects of long term oral angiotensin converting enzyme inhibitor in chronic heart failure. Circulation 59,60: 11–130Google Scholar
  27. 27.
    Sharpe DN, Douglas JE, Coxon RJ, Long B (1980) Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet 2: 1154–1157PubMedCrossRefGoogle Scholar
  28. 28.
    Turini GA, Brunner HR (1980) Les inhibiteurs du système rénine-angiotensine dans l’insuffisance cardiaque chronique. Extrait des «Journées de Réanimation» de l’Hôpital Claude-Bernard. Librairie Arnette, Paris, pp 307–315Google Scholar
  29. 29.
    Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M et al. (1981) Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 29 /5: 665–670PubMedCrossRefGoogle Scholar
  30. 30.
    Erdös EG (1976) Conversion of angiotensin Ito angiotensin II. Am J Med 60: 749–759PubMedCrossRefGoogle Scholar
  31. 31.
    Murthy VS, Waldron TL, Goldberg ME (1978) The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14.225, in conscious rabbits. Circ Res [Suppl 1] 43: 140–145Google Scholar
  32. 32.
    McGiff JC, Terragno NA, Malik KU, Lonigro AJ (1973) Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 31: 36–43Google Scholar
  33. 33.
    Textor SC, Brunner HR, Gavras H (1981) Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension 3 /2: 269–276PubMedGoogle Scholar
  34. 34.
    Gavras H, Brunner HR, Turini GA et al. (1978) Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14,225 in man. N Engl J Med 298: 991–995PubMedCrossRefGoogle Scholar
  35. 35.
    Brunner HR, Gavras H, Turini GA et al. (1979) Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 90: 19–23PubMedGoogle Scholar
  36. 36.
    Bravo EL, Tarazi RC (1979) Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1: 39–46PubMedGoogle Scholar
  37. 37.
    Gavras H, Liang C, Brunner HR (1978) Redistribution of regional blood flow after inhibition of the angiotensin-converting enzyme. Circ Res [Suppl 1] 43: 59–63Google Scholar
  38. 38.
    Mimran A, Brunner HR, Turini GA, Waeber B, Brunner DB (1979) Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci 57: 421s - 423sPubMedGoogle Scholar
  39. 39.
    Braunwald E, Ross J, Sonnenblick EH (1968) Mechanisms of contraction of the normal and failing heart. Little, Brown, Boston, pp 157–163Google Scholar
  40. 40.
    Davis JO, Freeman RH (1976) Mechanisms regulating renin release. Physiol Rev 56: 1–56PubMedGoogle Scholar
  41. 41.
    Spertini F, Brunner HR, Waeber B, Gavras H (1981) The opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs. norepinephrine in rats. Circ Res 48 /5: 612–618PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • G. A. Turini
  • H. R. Brunner

There are no affiliations available

Personalised recommendations